Health Canada Approves DAWNZERA® (donidalorsen) for the Prevention of Hereditary Angioedema Attacks
Approval marks CELYSTRA Pharma’s second product approved by Health Canada in…
Navigating uncertainty: impacts and adaptations for our sector
Together towards 2025: challenges and opportunities
2024 in retrospect
We have just started the 2025 Renewal Campaign!
September was a month rich in events and twists and turns.
The BIOQuébec team has been particularly active in recent weeks, preparing for a back-to-school season full of projects and…
During the first half of 2024, BIOQuébec experienced a very active period.
Read More
Read more
Approval marks CELYSTRA Pharma’s second product approved by Health Canada in…
We use cookies to improve your browsing experience and analyze our traffic. By clicking "Accept", you consent to our use of cookies.
Privacy Policy